Suji Udayakumar1, Eden Solomon1, Wanrudee Isaranuwatchai2, Danielle L Rodin3,4, Yoo-Joung Ko5,6, Kelvin K W Chan1,6,7,8, Ambica Parmar9,10. 1. Sunnybrook Research Institute, Toronto, ON, Canada. 2. Health Intervention and Technology Assessment Program, Bangkok, Thailand. 3. Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. 4. Princess Margaret Cancer Centre, Toronto, ON, Canada. 5. St. Michael's Hospital, Toronto, ON, Canada. 6. Department of Medicine, University of Toronto, Toronto, ON, Canada. 7. Odette Cancer Centre, Sunnybrook Health Sciences Centre, ON, Toronto, Canada. 8. Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada. 9. Department of Medicine, University of Toronto, Toronto, ON, Canada. ambika.parmar@sunnybrook.ca. 10. Odette Cancer Centre, Sunnybrook Health Sciences Centre, ON, Toronto, Canada. ambika.parmar@sunnybrook.ca.
Abstract
PURPOSE: In the past decade, literature has called attention to financial toxicities experienced by cancer patients. Though studies have addressed research questions in high-income countries, there remains a paucity of in-depth reviews regarding low- and middle-income countries (LMICs). Our scoping review provides an overview of treatment-related financial toxicities experienced by cancer patients in LMICs. METHODS: A systematic search was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. English peer-reviewed articles that (a) explored patients' experience with financial toxicity due to cancer treatment (b) were specific to LMICs as defined by the World Bank and (c) focused on qualitative data were included. Details regarding participants and main findings were extracted and synthesized. RESULTS: The search yielded 6290 citations, and 42 studies across 3 low-income, 9 lower-middle-income and 8 upper-middle-income countries. Main themes identified included cancer patients encountered various material hardships, managed costs with different coping behaviours and experienced negative psychological responses to their financial burden. Higher levels of financial toxicities were associated with patient characteristics such as lower socio-economic status and lack of insurance, as well as patient outcomes such as lower quality of life. CONCLUSION: Cancer patients in LMIC experience deleterious financial toxicities as a result of treatment. This comprehensive characterization of financial toxicities will better allow health systems to adopt evidence-based mitigation strategies to reduce the financial burden on patients.
PURPOSE: In the past decade, literature has called attention to financial toxicities experienced by cancer patients. Though studies have addressed research questions in high-income countries, there remains a paucity of in-depth reviews regarding low- and middle-income countries (LMICs). Our scoping review provides an overview of treatment-related financial toxicities experienced by cancer patients in LMICs. METHODS: A systematic search was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. English peer-reviewed articles that (a) explored patients' experience with financial toxicity due to cancer treatment (b) were specific to LMICs as defined by the World Bank and (c) focused on qualitative data were included. Details regarding participants and main findings were extracted and synthesized. RESULTS: The search yielded 6290 citations, and 42 studies across 3 low-income, 9 lower-middle-income and 8 upper-middle-income countries. Main themes identified included cancer patients encountered various material hardships, managed costs with different coping behaviours and experienced negative psychological responses to their financial burden. Higher levels of financial toxicities were associated with patient characteristics such as lower socio-economic status and lack of insurance, as well as patient outcomes such as lower quality of life. CONCLUSION: Cancer patients in LMIC experience deleterious financial toxicities as a result of treatment. This comprehensive characterization of financial toxicities will better allow health systems to adopt evidence-based mitigation strategies to reduce the financial burden on patients.
Authors: Ke Xu; David B Evans; Kei Kawabata; Riadh Zeramdini; Jan Klavus; Christopher J L Murray Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Andrea C Tricco; Erin Lillie; Wasifa Zarin; Kelly K O'Brien; Heather Colquhoun; Danielle Levac; David Moher; Micah D J Peters; Tanya Horsley; Laura Weeks; Susanne Hempel; Elie A Akl; Christine Chang; Jessie McGowan; Lesley Stewart; Lisa Hartling; Adrian Aldcroft; Michael G Wilson; Chantelle Garritty; Simon Lewin; Christina M Godfrey; Marilyn T Macdonald; Etienne V Langlois; Karla Soares-Weiser; Jo Moriarty; Tammy Clifford; Özge Tunçalp; Sharon E Straus Journal: Ann Intern Med Date: 2018-09-04 Impact factor: 25.391
Authors: Annie Alexander; Rohini Kaluve; Jyothi S Prabhu; Aruna Korlimarla; B S Srinath; Suraj Manjunath; Shekar Patil; K S Gopinath; T S Sridhar Journal: Indian J Palliat Care Date: 2019 Jan-Mar